Specific Kinase Inhibitory Peptides for Use in Treatment of Cancer and Inflammatory Disorders
- IP Title
- Inhibitors of Autophosphorylation Protein Kinases
- Detailed Technology Description
- None
- Supplementary Information
- Inventor: ZHANG, Meiyun
Priority Number: WO2011066721A1
IPC Current: C07K001628 | A61K003900 | A61K0039395 | C12N000518 | C12N001513
Assignee Applicant: The University of Hong Kong
Title: ANTL-IGF-IR ANTIBODIES AND USES THEREOF | ANTICORPS ANTI-IGF-IR ET LEURS UTILISATIONS
Usefulness: ANTL-IGF-IR ANTIBODIES AND USES THEREOF | ANTICORPS ANTI-IGF-IR ET LEURS UTILISATIONS
Summary: For treating a tumor or cancer in subject such as human, where the cancer is prostate cancer, breast cancer, liver cancer, or colon cancer (claimed).
Novelty: New isolated antibody that specifically binds to human insulin-like growth factor I receptor, useful for treating tumor or cancer e.g. prostate, breast or liver
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application Date
- Apr 19, 2004
- Application No.
- 7,189,694
- Others
-
- *Abstract
-
Potentially Treats Breast, Colon and Prostate Cancer by Effectively Blocking Kinase
This peptide specifically inhibits the autophosphorylation of Janus Kinase 2 (JAK2) and epidermal growth factor receptor (EGFR). The autophosphorylation kinase inhibitor has potential in the treatment of breast cancer, colon cancer, prostate cancer, and other cancers where aggressiveness is associated with EGFR receptor family members. The inhibitor should be useful also in the blocking of activities of inflammatory cytokines that use JAK2 kinase for function in diseases such as multiple sclerosis and arthritis.Applications
Treatement of cancers involving the EGFR family members and inflammatory diseases involving gamma interferon and other JAK2-dependent cytokines
Advantages
- The peptide (and family members) is readily synthesized on standard peptide synthesizers in bulk amounts making it readily available
- The inhibitor can completely block autophosphorylation of both kinases at concentrations, which effectively blocks their function, without toxicity to cells possessing the kinase activity
The Technology
The peptide inhibitor is only 12 amino acids long and specifically targets the autophosphorylation sites of JAK2 and EGFR. The latter is of particular interest in that the autophosphorylation of EGFR is complex involving up to 5 sites. The inhibitor can completely block autophosphorylation of both kinases at concentrations, which effectively blocks their function, without toxicity to cells possessing the kinase activity. This is considerably more sophisticated than the monoclonal antibody approach and directly targets a critical functional site of the kinase. It is felt that the specificity of inhibition of kinase activity is comparable to that of Gleevecôfor BCR-Abl in chronic myelogenous leukemia, except that the autophosphorylation site is targeted as opposed to the ATP-binding sites. Patent is pending on the invention, including family members and structural requirements for assembly of the specific kinase inhibitory peptides. This research was conducted in the laboratories of Dr. Howard Johnson.
- *IP Issue Date
- Jul 12, 2007
- *IP Publication Date
- Dec 30, 2004
- *Principal Investigator
-
Name: Howard Johnson
Department:
Name: Lawrence Flowers
Department:
Name: Mustafa Mujtaba
Department:
Name: Prem Subramaniam
Department:
- Country/Region
- USA
